Nauck, M <br/><br/>
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Mar 2016 
 - 203-16 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12591  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Blood Glucose--drug effects<br/>Diabetes Mellitus, Type 2--blood<br/>Dipeptidyl-Peptidase IV Inhibitors--pharmacology<br/>Glucagon-Like Peptide-1 Receptor--therapeutic use<br/>Humans<br/>Hypoglycemic Agents--pharmacology<br/>Incretins--pharmacology<br/>Insulin--metabolism<br/>Insulin Secretion<br/>Insulin-Secreting Cells--metabolism<br/>Glucagon-Like Peptide-1 Receptor Agonists